Bruce D. Hoechner
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Curtiss-Wright (CW) Eyes Earnings Beat, Adds Nuclear Simulator. Analysts are questioning whether Curtiss-Wright will again exceed earnings estimates in its upcoming report. The company also installed a Stage 1 simulator at TerraPower’s Natrium nuclear site in Kemmerer, Wyoming, highlighting its involvement in advanced reactor development. These developments keep the stock in focus as it trades near the lower end of its 52‑week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Transaction History
| NGVT | ▲ Buy | Grant | 1,904 | $0 | 4/30/2026 | View on chart |
| CW | ▼ Sell | Open Market | 1,900 | $851K | 6/5/2025 | View on chart |
| CW | ▲ Buy | Grant | 4,426 | $2.0M | 6/2/2025 | View on chart |
| NGVT | ▲ Buy | Grant | 4,057 | $0 | 5/1/2025 | View on chart |
| CW | ▲ Buy | Grant | 1,110 | $427K | 12/16/2024 | View on chart |
| NGVT | ▲ Buy | Grant | 2,800 | $0 | 4/24/2024 | View on chart |
| NGVT | ▲ Buy | Grant | 1,645 | $0 | 4/28/2023 | View on chart |
| NGVT | ▲ Buy | Grant | 326 | $0 | 2/17/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,727 | $259K | 2/14/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 974 | $147K | 2/12/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,019 | $154K | 2/10/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,076 | $162K | 2/9/2023 | View on chart |
| ROG | ▲ Buy | Grant | 3,832 | $0 | 2/9/2023 | View on chart |
| ROG | ▲ Buy | Grant | 12,190 | $0 | 2/14/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,457 | $397K | 2/12/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,066 | $291K | 2/10/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 10,711 | $2.9M | 2/9/2022 | View on chart |
| ROG | ▲ Buy | Grant | 24,095 | $0 | 2/9/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,333 | $363K | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Ingevity sets Q3 2026 earnings date; article discusses holding reasons
Ingevity announced the dates for its third‑quarter 2026 earnings release and the accompanying webcast. A recent Yahoo article outlined several points that investors have cited for maintaining their positions in the company. The upcoming earnings call may provide additional data that could influence market views.
Ingevity sets Q3 2026 earnings date; article discusses holding reasons. Ingevity announced the dates for its third‑quarter 2026 earnings release and the accompanying webcast. A recent Yahoo article outlined several points that investors have cited for maintaining their positions in the company. The upcoming earnings call may provide additional data that could influence market views.